This was a multicenter, randomized, double-blind, active-controlled and non-inferiority Phase II clinical trial, to evaluate the immunogenicity and safety of a fifth-dose booster of NDV-HXP-S, an egg-derived, inactivated COVID-19 vectored-vaccine virus using the Newcastle disease virus.
É. J. F. Peixoto de Miranda, José Alfredo de Sousa Moreira, Ricardo Sobhie Diaz et al.· Scientific Reports· 0 citations
ABSTRACT Argentine hemorrhagic fever (AHF) is a disease caused by the Junín virus (JUNV) that can be fatal in 15%–30% of untreated cases. Although JUNV is the only arenavirus for which efficient therapy and vaccination have been established, its administration is limited. In this study, hybridoma technology was used to...
The inpatient economic burden of hospitalized patients with Puumala virus (PUUV) infections in Styria, Austria’s primary endemic region, is quantified to identify hospitalization costs and early admission predictors of costs.
S. Hatzl, Christina Geiger, L. Kriegl et al.· Open Forum Infectious Diseas...· 0 citations
ABSTRACT Influenza B viruses contribute substantially to seasonal disease burden; however, the structural basis by which antibodies recognize the major glycoprotein hemagglutinin (HA) and mediate antiviral activity remains incompletely defined. Influenza B virus used to circulate as two antigenically distinct lineages,...
D. Bhavsar, Alesandro Civljak, Bruno Bonnettaz et al.· Journal of Virology· 0 citations
Evaluated the accuracy of AlphaFold 3 (AF3) in predicting immune complexes of a known class of bnAbs towards a conserved epitope on influenza hemagglutinin (HA) and resolved atomistic details with high-resolution SPA cryo-EM that explain challenges with AF3 immune complex prediction.
Morgan Gee, Pragati Sharma, Alesandra J. Rodriguez et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
